Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Etelcalcetide (Primary) ; Cinacalcet
- Indications Secondary hyperparathyroidism
- Focus Therapeutic Use
- Sponsors Amgen
- 20 Dec 2018 Planned End Date changed from 26 Nov 2019 to 13 Apr 2020.
- 20 Dec 2018 Planned primary completion date changed from 26 Nov 2019 to 13 Apr 2020.
- 23 Oct 2018 Planned End Date changed from 29 Jul 2019 to 26 Nov 2019.